Programme | Time (SGT) |
---|---|
Welcome Remarks by the Conference Chairman | |
Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Pietro Lampertico, Prof. Seng Gee Lim |
|
HBV Cure: definitions and prospects – Prof. Pietro Lampertico, Italy |
|
The Role of ICE-HBV in HBV functional cure – Prof. Massimo Levrero, France |
|
Are HBV flares necessary for functional cure? – Prof. Kumar Visvanathan, Australia |
|
Virological Insights into functional cure Moderators: Prof. Thomas Tu, Dr. Jayantha Gunaratne |
|
Is cccDNA silenced or lost in functional cure? – Prof. Massimo Levrero, France |
|
Removing integrated HBV – Prof. Thomas Tu, Australia |
|
New virological targets leading to functional cure – Prof. Pei Jer Chen, Taiwan |
|
Free Paper: The role of HBx in functional cure – Dr. Aravind Sivakumar, Singapore |
|
Free paper: BMP pathway is a target for functional cure – Dr. Jayantha Gunaratne |
|
Free paper: HBV functional cure is related to baseline qHBsAg and interferon response – Prof. Seng Gee Lim, Singapore |
|
Lunch | |
Immunological insights into functional cure Moderator: Dr. Valerie Chew |
|
What we have learnt from interrogating the liver microenvironment : A review – Dr. Ram DasGupta, Singapore |
|
Understanding the immune mechanisms to achieve functional cure – Prof. Eui-Cheol Shin, Korea |
|
Free Paper Presentations | |
Free paper: The Role of STING Signaling Pathway in Chronic Hepatitis B: Implications for Immune Status – Dr. Zhang Mingyuan |
|
Animal Models Moderator: Prof. Eui-Cheol Shin, Prof. Massimo Levrero |
|
A humanized animal model with matching immune system – Dr. Qingfeng Chen, Singapore |
|
Animal model forum: How to use animal models in HBV drug development – Prof. Pei-Jer Chen, Dr. Qingfeng Chen, Dr. Guofeng Cheng, Dr. Zhi Hong |
|
Capsid Assemby Modulators Moderator: Prof. Harry Janssen |
|
The role of Capsid Assembly Modulators in functional cure – Prof. Man Fung Yuen, Hong Kong |
|
Invited Pharma Presentations Moderator: Prof. Harry Janssen |
|
Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis (Virtual) – Dr. Marc Windisch, Assembly Biosciences |
|
Aligos Assets for HBV functional cure – Dr. Min Wu, Aligos Therapeutics |
|
Tea Break | |
Biomarkers Moderator: Prof. Seng Gee Lim |
|
Biomarkers for functional cure – Prof. Man-Fung Yuen, Hong Kong |
|
Free paper: progress in biomarker discovery for HBV functional cure – Dr. Zijie Lim, Singapore |
|
Invited Pharma Presentations | |
The performance and clinical utility of novel highly sensitive iTACT-HBsAg and iTACT-HBcrAg assays – Dr. Kazuyoshi Miyamoto, Fujirebio |
|
Your partner in HBV management (Virtual) – Dr. Mark Anderson, Abbott Diagnostics |
|
Closing remarks | |
End of day 1 |
The Science of HBV Cure Meeting 2024 Scientific Programme
July, 2024
26
July, 2024
27
Programme | Time (SGT) |
---|---|
Special Lecture Moderators: Prof.Thomas Tu, Prof. Massimo Levrero |
|
Gene Editing for complete cure: state of the art – Dr. Kosh Agarwal, United Kingdom |
|
RNA interference Moderators: Prof. Thomas Tu, Prof. Massimo Levrero |
|
Anti-sense vs siRNA: can we explain the efficacy differences? – Prof. Pei-Jer Chen, Taiwan |
|
Invited Pharma Presentations Moderators: Prof. Thomas Tu, Prof. Massimo Levrero |
|
Roche strategy for functional cure – Dr. Farouk Chughlay, Roche |
|
Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis – Dr. Shilpy Joshi, GSK |
|
AHB-137, a novel ASO for HBV Cure – Dr. Guofeng Cheng, Ausperbio Therapeutics Inc |
|
Update on Nucleic Acid Polymers (Virtual) – Dr. Andrew Vaillant, Replicor |
|
Tea Break | |
Delta Cure Moderator: Prof. Lim Seng Gee |
|
Path to Delta Cure – Prof. Heiner Wedemeyer, Germany |
|
The role of NAPs in Delta Therapy (Virtual) – Dr. Andrew Valliant, Replicor |
|
Immunology Chair and moderator: Dr. Valerie Chew |
|
Insights into HBV Cure from studies of novel immune modulators (Virtual) – Prof. Antonio Bertoletti, Singapore |
|
Free paper: The differentiation of Treg and Th17 cells in patients with chronic hepatitis B in different stages – Dr. Le Thi Thuy Hang, Vietnam |
|
Lunch | |
Invited pharma Presentations Moderators: Prof. Kumar Visvanathan |
|
Characterisation of Selgantolimod (TLR8 agonist) against CHB (Virtual) – Dr. Frida Abramov, Gilead Sciences |
|
Clonal amplification of peripheral CD8+ T cells is associated with clinical response to checkpoint blockade in chronic hepatitis B (Virtual) – Dr. Jeff Wallin, Gilead Sciences |
|
Insights into CHB functional cure from Ascletis studies (Virtual) – Dr. Jinzi J. Wu, Founder, Chairman and CEO, Ascletis |
|
Achieving breakthroughs in HBV Cure – Dr. Zhi Hong, Brii Bio |
|
siRNA+Neutralizing antibody combination for HBV Cure – Dr. Wang Dong, Hepa Thera |
|
The potential role for a novel class, a Checkpoint Modifier, in the functional cure of CHB: the science and clinical data from VRON-0200 (Virtual) – Dr. Sue Currie, Dr. Andrew Luber, Virion Therapeutics |
|
Tea Break | |
Treatment strategies Moderators: Prof. Heiner Wedemeyer |
|
Potential of immune based therapies for functional cure: success and limitations – Prof. Tatsuya Kanto, Japan |
|
The return of interferon in functional cure strategies – a step backwards? – Prof. Harry Janssen, Holland |
|
Combination Therapy Forum Moderators: Prof. Seng Gee Lim, Prof. Heiner Wedemeyer |
|
Immunotherapy and antiviral therapy forum – Prof. Eui Choel Shin, Prof. Massimo Levrero, Prof. Thomas Tu, Prof. Harry Janssen, Prof. Pei-Jer Chen, Prof. Kumar Visvanathan, Dr. Zhi Hong, Dr. Melanie Paff, Dr. Guofeng Cheng |
|
Closing remarks from Chairman |